Dr. Campelo on the Rationale for the ALTA-1L Trial

Rosario Garcia Campelo, MD
Published: Tuesday, Sep 10, 2019



Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, discusses a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer who were treated with brigatinib (Alunbrig) versus crizotinib (Xalkori).
 
The study, updated quality-of-life data of which were presented at the 2019 World Conferenc on Lung Cancer, demonstrated that brigatinib is favorable in these patients, including those with brain metastases. Overall, brigatinib was superior in improving health-related quality of life.

  <<< 2019 World Conference on Lung Cancer


Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, discusses a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer who were treated with brigatinib (Alunbrig) versus crizotinib (Xalkori).
 
The study, updated quality-of-life data of which were presented at the 2019 World Conferenc on Lung Cancer, demonstrated that brigatinib is favorable in these patients, including those with brain metastases. Overall, brigatinib was superior in improving health-related quality of life.

  <<< 2019 World Conference on Lung Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x